# US 2024/0094220 A1 · Engineering bacillus subtilis as a versatile and stable platform for production of nanobodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0094220 A1
- Document ID: US20240094220A1
- Status: Published application
- Kind: A1
- Application number: 17/768,094
- Filed: 2020-10-13
- Published: 2024-03-21
- Earliest claimed: 2019-10-11
- Assignees: Northeastern University
- Applicants: Northeastern University
- Inventors: Jiahe Li
- Web page: https://patentgrep.com/patent/US20240094220A1

## CPC

- G01N 33/6854: {Immunoglobulins}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/082: Hepadnaviridae (F), e.g. hepatitis B virus
- C07K 16/104: Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- C07K 17/12: Cellulose or derivatives thereof
- C12N 1/205: Bacterial isolates
- C12N 15/75: for Bacillus
- G01N 33/532: Production of labelled immunochemicals
- C07K 2317/10: characterized by their source of isolation or production
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- G01N 2333/02: Hepadnaviridae, e.g. hepatitis B virus
- G01N 2333/165: Coronaviridae, e.g. avian infectious bronchitis virus
- G01N 2333/32: from Bacillus (G)
- G01N 2333/4603: from fish
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided are methods and pharmaceutical compositions related to nanobodies from engineered Bacillus subtilis bacteria which can be useful as therapeutic agents or for diagnostic testing.

## Claims

### Claim 1

A nanobody comprising a variable domain of an antibody, wherein the nanobody is contained within a Bacillus subtilis bacteria strain.

### Claim 2 (depends on 1)

The nanobody of claim 1, wherein the variable domain is a heavy chain variable domain.

### Claim 3 (depends on 1, 2)

The nanobody of claim 1 or 2, wherein the antibody is a mammalian antibody.

### Claim 4 (depends on 3)

The nanobody of claim 3, wherein the mammalian antibody is a camelid antibody.

### Claim 5 (depends on 1, 2)

The nanobody of claim 1 or 2, wherein the antibody is a fish antibody.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The nanobody of any one of claim 1-5, wherein the Bacillus subtilis strain is deficient in at least eight extracellular proteases.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The nanobody of any one of claims 1-6, wherein the Bacillus subtilis strain comprises at least 90% genomic, 16S and/or CRISPR sequence identity to the nucleotide sequence of Bacillus subtilis strain WB800N (GenBank Accession No. CP032310.1).

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

The nanobody of any one of claims 1-6, wherein the Bacillus subtilis strain comprises at least 99% genomic, 16S and/or CRISPR sequence identity to the nucleotide sequence of Bacillus subtilis strain WB800N (GenBank Accession No. CP032310.1).

### Claim 9 (depends on 1, 2, 3, 4, 5, 6)

The nanobody of any one of claims 1-6, wherein the Bacillus subtilis strain is Bacillus subtilis strain WB800N (GenBank Accession No. CP032310.1).

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The nanobody of any one of claims 1-9, further comprising an affinity tag.

### Claim 11 (depends on 10)

The nanobody of claim 10, wherein the affinity tag binds to an immobile substrate.

### Claim 12 (depends on 11)

The nanobody of claim 11, wherein the immobile substrate is a cellulose substrate.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The nanobody of any one of claims 1-12, wherein the nanobody is conjugated to a drug.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The nanobody of any one of claims 1-13, wherein the nanobody is conjugated to a label.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The nanobody of any one of claims 1-14, wherein the nanobody binds to a target antigen.

### Claim 16 (depends on 15)

The nanobody of claim 15, wherein the target antigen is a small molecule.

### Claim 17 (depends on 16)

The nanobody of claim 16, wherein the small molecule is methotrexate.

### Claim 18 (depends on 17)

The nanobody of claim 17, wherein the nanobody comprises a nucleic acid sequence that is at least 80% identical to SEQ ID NO. 1.

### Claim 19 (depends on 17)

The nanobody of claim 17, wherein the nanobody comprises a nucleic acid sequence that is at least 90% identical to SEQ ID NO. 1.

### Claim 20 (depends on 17)

The nanobody of claim 17, wherein the nanobody comprises SEQ ID NO. 1.

### Claim 21 (depends on 16)

The nanobody of claim 16, wherein the small molecule is caffeine.

### Claim 22 (depends on 21)

The nanobody of claim 21, wherein the nanobody comprises a nucleic acid sequence that is at least 80% identical to SEQ ID NO. 2.

### Claim 23 (depends on 21)

The nanobody of claim 21, wherein the nanobody comprises a nucleic acid sequence that is at least 90% identical to SEQ ID NO. 2.

### Claim 24 (depends on 21)

The nanobody of claim 21, wherein the nanobody comprises SEQ ID NO. 2.

### Claim 25 (depends on 15)

The nanobody of claim 15, wherein the target antigen is a eukaryotic cell surface protein.

### Claim 26 (depends on 25)

The nanobody of claim 25, wherein the eukaryotic cell surface protein is an immune checkpoint ligand.

### Claim 27 (depends on 26)

The nanobody of claim 26, wherein the immune checkpoint ligand is PD-L1.

### Claim 28 (depends on 27)

The nanobody of claim 27, wherein the nanobody comprises an amino acid sequence that is at least 80% identical to SEQ ID NO. 3.

### Claim 29 (depends on 27)

The nanobody of claim 27, wherein the nanobody comprises an amino acid sequence that is at least 90% identical to SEQ ID NO. 3.

### Claim 30 (depends on 27)

The nanobody of claim 27, wherein the nanobody comprises SEQ ID NO. 3.

### Claim 31 (depends on 26)

The nanobody of claim 26, wherein the immune checkpoint ligand is CTLA-4.

### Claim 32 (depends on 31)

The nanobody of claim 31, wherein the nanobody comprises an amino acid sequence that is at least 80% identical to SEQ ID NO. 4.

### Claim 33 (depends on 31)

The nanobody of claim 31, wherein the nanobody comprises an amino acid sequence that is at least 90% identical to SEQ ID NO. 4.

### Claim 34 (depends on 31)

The nanobody of claim 31, wherein the nanobody comprises SEQ ID NO. 4.

### Claim 35 (depends on 15)

The nanobody of claim 15, wherein the target antigen is a viral antigen.

### Claim 36 (depends on 35)

The nanobody of claim 35, wherein the viral antigen is a SARS-CoV-2 antigen.

### Claim 37 (depends on 36)

The nanobody of claim 36, wherein the SARS-CoV-2 antigen is a spike glycoprotein.

### Claim 38 (depends on 35)

The nanobody of claim 35, wherein the viral antigen is a hepatitis B antigen.

### Claim 39 (depends on 38)

The nanobody of claim 38, wherein the hepatitis B antigen is hepatitis B surface antigen (HBsAg).

### Claim 40 (depends on 38)

The nanobody of claim 38, wherein the hepatitis B antigen is hepatitis B e-antigen (HBeAg).

### Claim 41 (depends on 38)

The nanobody of claim 38, wherein the hepatitis B antigen is hepatitis B core antigen (HBcAg).

### Claim 42 (depends on 15)

The nanobody of claim 15, wherein the target antigen is an inflammatory cytokine.

### Claim 43 (depends on 42)

The nanobody of claim 42, wherein the inflammatory cytokine is TNF-α.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

A cell culture supernatant of a Bacillus subtilis strain comprising a nanobody of any one of claims 1-43.

### Claim 45 (depends on 44)

The cell culture supernatant of claim 44, wherein the Bacillus subtilis strain is deficient in at least eight extracellular proteases.

### Claim 46 (depends on 44, 45)

The cell culture supernatant of claim 44 or 45, wherein the Bacillus subtilis strain comprises at least 90% genomic, 16S and/or CRISPR sequence identity to the nucleotide sequence of Bacillus subtilis strain WB800N (GenBank Accession No. CP032310.1).

### Claim 47 (depends on 44, 45)

The cell culture supernatant of claim 44 or 45, wherein the Bacillus subtilis strain comprises at least 99% genomic, 16S and/or CRISPR sequence identity to the nucleotide sequence of Bacillus subtilis strain WB800N (GenBank Accession No. CP032310.1).

### Claim 48 (depends on 44, 45)

The cell culture supernatant of claim 44 or 45, wherein the Bacillus subtilis strain is Bacillus subtilis strain WB800N (GenBank Accession No. CP032310.1).

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

A vegetative cell of a Bacillus subtilis strain comprising a nanobody of any one of claims 1-43.

### Claim 50 (depends on 49)

The vegetative cell of claim 49, wherein the Bacillus subtilis strain is deficient in at least eight extracellular proteases.

### Claim 51 (depends on 49, 50)

The vegetative cell of claim 49 or 50, wherein the Bacillus subtilis strain comprises at least 90% genomic, 16S and/or CRISPR sequence identity to the nucleotide sequence of Bacillus subtilis strain WB800N (GenBank Accession No. CP032310.1).

### Claim 52 (depends on 49, 50)

The vegetative cell of claim 49 or 50, wherein the Bacillus subtilis strain comprises at least 99% genomic, 16S and/or CRISPR sequence identity to the nucleotide sequence of Bacillus subtilis strain WB800N (GenBank Accession No. CP032310.1).

### Claim 53 (depends on 49, 50)

The vegetative cell of claim 49 or 50, wherein the Bacillus subtilis strain is Bacillus subtilis strain WB800N (GenBank Accession No. CP032310.1).

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

A vector comprising a polynucleotide encoding a nanobody of any one of claims 1-43.

### Claim 55 (depends on 54)

A sporulated cell of a Bacillus subtilis strain comprising a vector of claim 54.

### Claim 56 (depends on 55)

The sporulated cell of claim 55, wherein the Bacillus subtilis strain is deficient in at least eight extracellular proteases.

### Claim 57 (depends on 55, 56)

The sporulated cell of claim 55 or 56, wherein the Bacillus subtilis strain comprises at least 90% genomic, 16S and/or CRISPR sequence identity to the nucleotide sequence of Bacillus subtilis strain WB800N (GenBank Accession No. CP032310.1).

### Claim 58 (depends on 55, 56)

The sporulated cell of claim 55 or 56, wherein the Bacillus subtilis strain comprises at least 99% genomic, 16S and/or CRISPR sequence identity to the nucleotide sequence of Bacillus subtilis strain WB800N (GenBank Accession No. CP032310.1).

### Claim 59 (depends on 55, 56)

The sporulated cell of claim 55 or 56, wherein the Bacillus subtilis strain is Bacillus subtilis strain WB800N (GenBank Accession No. CP032310.1).

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

A pharmaceutical composition comprising a nanobody of any one of claims 1-43.

### Claim 61 (depends on 44, 45, 46, 47, 48)

A pharmaceutical composition comprising a cell culture supernatant of any one of claims 44-48.

### Claim 62 (depends on 49, 50, 51, 52, 53)

A pharmaceutical composition comprising a vegetative cell of any one of claims 49-53.

### Claim 63 (depends on 55, 56, 57, 58, 59)

A pharmaceutical composition comprising a sporulated cell of any one of claims 55-59.

### Claim 64 (depends on 60, 61, 62, 63)

Use of a pharmaceutical composition of any one of claims 60-63 for the preparation of a medicament for the treatment or prevention of a disease or disorder.

### Claim 65 (depends on 64)

The use of claim 64, wherein the disease or disorder is a gastrointestinal disease.

### Claim 66 (depends on 64)

The use of claim 64, wherein the disease or disorder is an immunoinflammatory disease.

### Claim 67 (depends on 64)

The use of claim 64, wherein the disease or disorder is a metabolic disorder.

### Claim 68 (depends on 64)

The use of claim 64, wherein the disease or disorder is a cancer.

### Claim 69 (depends on 64)

The use of claim 64, wherein the disease or disorder is an infectious disease.

### Claim 70 (depends on 69)

The of claim 69, wherein the infectious disease is a viral infection.

### Claim 71 (depends on 70)

The use of claim 70, wherein the viral infection is COVID-19.

### Claim 72 (depends on 70)

The use of claim 70, wherein the viral infection is hepatitis B infection.

### Claim 73 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72)

The use of any one of claims 64-72, wherein the medicament comprises an additional therapeutic.

### Claim 74 (depends on 73)

The use of claim 73, wherein the additional therapeutic is an anti-inflammatory agent.

### Claim 75 (depends on 73)

The use of claim 73, wherein the additional therapeutic is a chemotherapeutic agent.

### Claim 76 (depends on 73)

The use of claim 73, wherein the additional therapeutic is an immunotherapy agent.

### Claim 77 (depends on 76)

The use of claim 76, wherein the immunotherapy is an immune checkpoint inhibitor.

### Claim 78 (depends on 73)

The use of claim 73, wherein the additional therapeutic is an anti-viral agent.

### Claim 79 (depends on 60, 61, 62, 63)

A method of treating a disease or disorder, comprising administering to a subject in need thereof an effective amount of the pharmaceutical composition of any one of claims 60-63.

### Claim 80 (depends on 79)

The method of claim 79, wherein the disease or disorder is a gastrointestinal disease.

### Claim 81 (depends on 79)

The method of claim 79, wherein the disease or disorder is a metabolic disorder.

### Claim 82 (depends on 79)

The method of claim 79, wherein the disease or disorder is an immunoinflammatory disease.

### Claim 83 (depends on 79)

The method of claim 79, wherein the disease or disorder is a cancer.

### Claim 84 (depends on 79)

The method of claim 79, wherein the disease or disorder is an infectious disease.

### Claim 85 (depends on 84)

The method of claim 84, wherein the infectious disease is a viral infection.

### Claim 86 (depends on 85)

The method of claim 85, wherein the viral infection is COVID-19.

### Claim 87 (depends on 85)

The method of claim 85, wherein the viral infection is hepatitis B infection.

### Claim 88 (depends on 79, 80, 81, 82, 83, 84, 85, 86, 87)

The method of any one of claims 79-87, further comprising conjointly administering to the subject an effective amount of an additional therapeutic.

### Claim 89 (depends on 88)

The method of claim 88, wherein the additional therapeutic is an anti-inflammatory agent.

### Claim 90 (depends on 88)

The method of claim 88, wherein the additional therapeutic is a chemotherapeutic agent.

### Claim 91 (depends on 88)

The method of claim 88, wherein the additional therapeutic is an immunotherapy agent.

### Claim 92 (depends on 91)

The method of claim 91, wherein the immunotherapy is an immune checkpoint inhibitor.

### Claim 93 (depends on 88)

The method of claim 88, wherein the additional therapeutic is an anti-viral agent.

### Claim 94 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

A method of inhibiting virus fusion to a human cell, comprising contacting the virus with an nanobody of any one of claims 1-43.

### Claim 95 (depends on 94)

The method of claim 94, wherein the virus is SARS-CoV-2 virus.

### Claim 96 (depends on 94)

The method of claim 94, wherein the virus is hepatitis B virus.

### Claim 97 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 54)

A method of producing the nanobody of any one of claims 1-43, comprising the steps of:
a) expressing the vector of claim 54 in a Bacillus subtilis strain; and
b) harvesting the nanobody from the Bacillus subtilis strain or a cell culture supernatant of the Bacillus subtilis strain.

### Claim 98 (depends on 97)

The method of claim 97, wherein the nanobody comprises an affinity tag.

### Claim 99 (depends on 98)

The method of claim 98, further comprising isolating the nanobody on an immobile substrate by binding of the affinity tag to the immobile substrate.

### Claim 100 (depends on 99)

The method of claim 99, wherein the immobile substrate is a cellulose substrate.

### Claim 101 (depends on 97, 98, 99, 100)

The method of any one of claims 97-100, wherein the Bacillus subtilis strain secretes the nanobody.

### Claim 102 (depends on 97, 98, 99, 100, 101)

The method of any one of claims 97-101, wherein the Bacillus subtilis strain is deficient in at least eight extracellular proteases.

### Claim 103 (depends on 97, 98, 99, 100, 101, 102)

The method of any one of claims 97-102, wherein the Bacillus subtilis strain comprises at least 90% genomic, 16S and/or CRISPR sequence identity to the nucleotide sequence of Bacillus subtilis strain WB800N (GenBank Accession No. CP032310.1).

### Claim 104 (depends on 97, 98, 99, 100, 101, 102)

The method of any one of claims 97-102, wherein the Bacillus subtilis strain comprises at least 99% genomic, 16S and/or CRISPR sequence identity to the nucleotide sequence of Bacillus subtilis strain WB800N (GenBank Accession No. CP032310.1).

### Claim 105 (depends on 97, 98, 99, 100, 101, 102)

The method of any one of claims 97-102, wherein the Bacillus subtilis strain is Bacillus subtilis strain WB800N (GenBank Accession No. CP032310.1).

### Claim 106 (depends on 101, 102, 103, 104, 105)

The method of any one of claims 101-105, wherein the nanobody is harvested from the cell culture supernatant of the Bacillus subtilis strain.

### Claim 107 (depends on 97, 98, 99, 100, 101, 102, 103, 104, 105, 106)

The method any one of claims 97-106, wherein the Bacillus subtilis strain is a sporulated Bacillus subtilis strain prior to step (a).

### Claim 108 (depends on 107)

The method of claim 107, wherein the sporulated Bacillus subtilis strain is germinated into a vegetative Bacillus subtilis strain prior to step (a).

### Claim 109 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

A method of detecting the presence of a target antigen in a sample, comprising incubating the nanobody of any one of claims 1-43 with the sample, wherein the nanobody comprises a detectable label.

### Claim 110 (depends on 109)

The method of claim 109, wherein the target antigen is a small molecule.

### Claim 111 (depends on 110)

The method of claim 110, wherein the small molecule is methotrexate.

### Claim 112 (depends on 110)

The method of claim 110, wherein the small molecule is caffeine.

### Claim 113 (depends on 109)

The method of claim 109, wherein the target antigen is a eukaryotic cell surface protein.

### Claim 114 (depends on 113)

The method of claim 113, wherein the eukaryotic cell surface protein is an immune checkpoint ligand.

### Claim 115 (depends on 114)

The method of claim 114, wherein the immune checkpoint ligand is PD-L1.

### Claim 116 (depends on 114)

The method of claim 114, wherein the immune checkpoint ligand is CTLA-4.

### Claim 117 (depends on 109)

The method of claim 109, wherein the target antigen is a viral antigen.

### Claim 118 (depends on 117)

The method of claim 117, wherein the viral antigen is a SARS-CoV-2 antigen.

### Claim 119 (depends on 118)

The method of claim 118, wherein the SARS-CoV-2 antigen is a spike glycoprotein.

### Claim 120 (depends on 117)

The method of claim 117, wherein the viral antigen is a hepatitis B antigen.

### Claim 121 (depends on 120)

The method of claim 120, wherein the hepatitis B antigen is hepatitis B surface antigen (HBsAg).

### Claim 122 (depends on 120)

The method of claim 120, wherein the hepatitis B antigen is hepatitis B e-antigen (HBeAg).

### Claim 123 (depends on 120)

The method of claim 120, wherein the hepatitis B antigen is hepatitis B core antigen (HBcAg).

### Claim 124 (depends on 109)

The method of claim 109, wherein the target antigen is an inflammatory cytokine.

### Claim 125 (depends on 124)

The method of claim 124, wherein the inflammatory cytokine is TNF-α.

### Claim 126 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

A kit for detecting a target antigen in a sample, comprising a device for collecting the sample and reagents for detecting the target antigen, wherein the reagents comprise the nanobody of any one of claims 1-43, and the nanobody comprises a detectable label.

### Claim 127 (depends on 126)

The kit of claim 126, wherein the target antigen is a small molecule.

### Claim 128 (depends on 127)

The kit of claim 127, wherein the small molecule is methotrexate.

### Claim 129 (depends on 127)

The kit of claim 127, wherein the small molecule is caffeine.

### Claim 130 (depends on 126)

The kit of claim 126, wherein the target antigen is a eukaryotic cell surface protein.

### Claim 131 (depends on 130)

The kit of claim 130, wherein the eukaryotic cell surface protein is an immune checkpoint ligand.

### Claim 132 (depends on 131)

The kit of claim 131, wherein the immune checkpoint ligand is PD-L1.

### Claim 133 (depends on 131)

The kit of claim 131, wherein the immune checkpoint ligand is CTLA-4.

### Claim 134 (depends on 126)

The kit of claim 126, wherein the target antigen is a viral antigen.

### Claim 135 (depends on 134)

The kit of claim 134, wherein the viral antigen is a SARS-CoV-2 antigen.

### Claim 136 (depends on 135)

The kit of claim 135, wherein the SARS-CoV-2 antigen is a spike glycoprotein.

### Claim 137 (depends on 134)

The kit of claim 134, wherein the viral antigen is a hepatitis B antigen.

### Claim 138 (depends on 137)

The kit of claim 137, wherein the hepatitis B antigen is hepatitis B surface antigen (HBsAg).

### Claim 139 (depends on 137)

The kit of claim 137, wherein the hepatitis B antigen is hepatitis B e-antigen (HBeAg).

### Claim 140 (depends on 137)

The kit of claim 137, wherein the hepatitis B antigen is hepatitis B core antigen (HBcAg).

### Claim 141 (depends on 126)

The kit of claim 126, wherein the target antigen is an inflammatory cytokine.

### Claim 142 (depends on 141)

The kit of claim 141, wherein the inflammatory cytokine is TNF-α.
